Products

Frequently Asked Questions and Answers:

1.What to do after detection of high risk or increased risk of tumor incidence?
The final reports provide preventive health management programs for your reference specific to the high risk or increased risk of carcinogenesis, at the same time, It is recommended that you discuss the test results with your doctor to decide the appropriate preventive measures.

2.Will the patients develop into tumor carriers for sure after detection of high risk or increased risk of tumor incidence?
On one hand, detection of high risk or increased risk means there are mutations in the hereditary cancer susceptibility genes. The patients get much higher chance to develop certain tumors than healthy population. But it does not mean that they will get cancers in the future, so the patients should avoid panic, depression at first. On the other hand, the testing results prompt patients to pay attention to the prevention of cancers, to do regular health examinations so as to achieve early detection, early diagnosis and early treatment of the diseases.

3.Do all malignant tumors have a genetic predisposition?
Only part of the malignant tumors are genetic predisposition, but tumors are not directly inherited from parents, it can only be described as a genetic predisposition with increased risk of cancer development. Though there are nearly 200 types of cancers clinically diagnosed, they all are attributed to the results of one or more oncogenic genes from the perspective of genetics and Cytology. Simply speaking, cancers have certain features of genetic predisposition, this is not equivalent to the notion that cancers are genetic diseases and will definitely pass on to the next generations by 100%.

about us
about us

Jiuzhou Genetics focuses on the application of high-throughput sequencing and other cutting-edge biotechnologies in human medical and healthcare fields. We concentrate on the field of personal genomics, aiming to provide the best professional services on genetic counseling for Chinese, molecular diagnosis of the highest quality and the world-leading precise individualized treatment regimens as high-end services to our clients. This company was established in September of 2016 and registered in the central Science & Technology Park of Shijingshan region in Beijing.